← The Wire
SGMTNasdaq
Sagimet Biosciences Inc.
Pharmaceutical Preparations · DE · CIK 1400118
Developing novel FASN inhibitors for metabolic and fibrotic diseases like MASH, acne, and cancer
red 8-K · 90d
$400M
Market cap
$7.79
Last close
+10.3%
1D
+9.7%
5D
1.4M
Volume
Price · last 39 sessions-1.4%
May 4L $6.30 · H $8.38Jun 29
82
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 12, 20268-KExecutive ChangeJun 3, 20268-KResults of OperationsMay 12, 202610-Q10-QMay 12, 20268-KMaterial AgreementApr 28, 2026424B5424B5Apr 28, 20268-KReg FD DisclosureApr 27, 20268-KResults of Operations · Reg FD DisclosureApr 27, 2026DEF 14ADEF 14AApr 21, 20268-KExecutive Change · Company UpdateApr 21, 20268-KResults of Operations · Reg FD DisclosureMar 11, 202610-K10-KMar 11, 20268-KReg FD DisclosureFeb 2, 20268-KReg FD Disclosure · Company UpdateDec 18, 20258-KCompany UpdateDec 17, 20258-KResults of Operations · Reg FD DisclosureNov 13, 202510-Q10-QNov 13, 20258-KReg FD DisclosureOct 23, 20258-KAuditor ChangeAug 22, 20258-KMaterial Agreement · Agreement TerminatedAug 14, 2025424B5424B5Aug 14, 20258-KResults of Operations · Reg FD DisclosureAug 13, 202510-Q10-QAug 13, 20258-KExecutive Change · Shareholder VoteJun 10, 20258-KReg FD DisclosureJun 4, 20258-KResults of Operations · Company UpdateMay 8, 202510-Q10-QMay 8, 20258-KExecutive ChangeApr 30, 2025DEF 14ADEF 14AApr 30, 20258-KResults of Operations · Company UpdateMar 12, 202510-K10-KMar 12, 20258-KCompany UpdateMar 11, 20258-KCompany UpdateFeb 14, 20258-KCompany UpdateJan 2, 2025SC 13GSC 13GNov 14, 20248-KResults of OperationsNov 14, 202410-Q10-QNov 14, 20248-KMaterial AgreementAug 16, 20248-KResults of Operations · Company UpdateAug 14, 202410-Q10-QAug 14, 20248-KExecutive ChangeAug 1, 20248-KCompany UpdateJul 2, 20248-K/ACompany UpdateJun 13, 20248-KShareholder Vote · Company UpdateJun 6, 20248-KReg FD DisclosureMay 23, 20248-KResults of OperationsMay 15, 202410-Q10-QMay 15, 20248-KExecutive ChangeMay 6, 2024DEFA14ADEFA14AApr 18, 2024DEF 14ADEF 14AApr 18, 202410-K10-KMar 25, 20248-KExecutive Change · Results of OperationsMar 25, 2024SC 13GNEW ENTERPRISE ASSOCIATES 13, L.P. / SAGIMET BIOSCIENCES -- 13GFeb 14, 2024SC 13GSAGIMET BIOSCIENCES INC.Feb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GSC 13GFeb 14, 2024SC 13GSAGIMET BIOSCIENCES INC.Feb 5, 20248-KExecutive ChangeFeb 2, 20248-KCompany UpdateJan 30, 2024424B4S-1/AJan 29, 20248-KResults of OperationsJan 24, 2024S-1/AS-1/AJan 24, 2024S-1FORM S-1Jan 23, 20248-KReg FD Disclosure · Company UpdateJan 22, 20248-KExecutive Change · Reg FD DisclosureDec 29, 20238-KExecutive ChangeNov 21, 20238-KResults of OperationsNov 13, 202310-Q10-QNov 13, 20238-KReg FD DisclosureOct 23, 20238-KReg FD Disclosure · Company UpdateSep 27, 2023SC 13GSC 13GSep 11, 20238-KResults of Operations · Reg FD DisclosureAug 21, 202310-QFORM 10-QAug 21, 20238-KReg FD DisclosureAug 10, 20238-KExecutive ChangeJul 27, 20238-KBylaw AmendmentJul 18, 2023424B4424B4Jul 17, 2023S-1/AS-1/AJul 10, 2023S-1/AS-1/AJul 3, 2023S-1S-1Jun 23, 2023
Insider Activity
In the 90 days to Feb 10, 2026: 5 sold $395K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Happel DavidPresident & CEO | Sell | 12,101 | $5.36 | $65K |
| Feb 10, 2026 | Martins Eduardo BrunoChief Medical Officer | Sell | 3,640 | $5.36 | $20K |
| Feb 10, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sell | 2,622 | $5.36 | $14K |
| Feb 10, 2026 | Chauche ThierryChief Financial Officer | Sell | 1,312 | $5.36 | $7K |
| Nov 20, 2025 | Kemble GeorgeExecutive Chairman | Sell | 37,688 | $7.69 | $290K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance